The effect of treatment as usual on major depressive disorder: A meta-analysis

被引:49
|
作者
Kolovos, Spyros [1 ,2 ]
van Tulder, Maurits W. [1 ,2 ]
Cuijpers, Pim [3 ,4 ]
Prigent, Amelie [5 ,6 ]
Chevreul, Karine [5 ,6 ,7 ,8 ]
Riper, Heleen [3 ,4 ]
Bosmans, Judith E. [1 ,2 ]
机构
[1] Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Hlth Sci, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Fac Earth & Life Sci, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Fac Behav & Movement Sci, Dept Clin Neuro & Dev Psychol, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam, Fac Behav & Movement Sci, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands
[5] URC Eco Ile France, AP HP, Paris, France
[6] Univ Paris Diderot, Sorbonne Paris Cite, ECEVE, Paris, France
[7] Vrije Univ Amsterdam, Med Ctr Amsterdam, GGZ inGeest, Dept Psychiat, Amsterdam, Netherlands
[8] Vrije Univ Amsterdam, Med Ctr Amsterdam, GGZ inGeest, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands
关键词
Major depression; Treatment as usual; Meta-analysis; Health-economic models; MENTAL-HEALTH-CARE; QUALITY-OF-LIFE; ADULTS; PSYCHOTHERAPY; REMISSION; BURDEN; BIAS; INTERVENTIONS; RECOVERY; DISEASE;
D O I
10.1016/j.jad.2016.12.013
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Health-economic models are used to evaluate the long-term cost-effectiveness of an intervention and typically include treatment as usual (TAU) as comparator. Part of the data used for these models are acquired from the literature and thus valid information is needed on the effects of TAU on depression. The aim of the current meta-analysis was to examine positive and negative outcomes of major depression for patients receiving TAU. Methods: We conducted a systematic literature search in PubMed, EMBASE, Psyclnfo, and the Cochrane Central Register of Controlled Trials. Eligible studies were randomized controlled trials including a TAU group for depression. The quality of the included studies was assessed using the criteria described in the "Risk of bias assessment tool". Four separate meta-analyses were performed to estimate remission, response, reliable change and deterioration rates at short-term (<= 6 months from baseline). Results: Thirty-eight studies including 2099 patients in the TAU were identified. Nine studies (24%) met five or six quality criteria, 17 studies (44%) met three or four quality criteria and 12 studies (32%) met one or two quality criteria. After adjusting for publication bias, the first meta-analysis (n=33) showed that 33% of the patients remitted from depression. The second meta-analysis (n=13) demonstrated that 27% of the patients responded to treatment, meaning that their depressive symptom decreased at least 50% from baseline to follow-up measurement. The third meta-analysis (n=7) indicated that 31% of the patients showed a reliable change, meaning that their depressive symptoms improved more than expected by random variation alone. Finally, 12% of the patients deteriorated, meaning that their depressive symptoms became more severe. Limitations: Statistical heterogeneity was substantial in most analyses and was not fully explained by subgroup analyses. The quality of the included studies was moderate. This may result in overestimation of the true effects. Conclusions: The treatments labelled as TAU for depression were clinically and statistically heterogeneous. We demonstrated that a few patients benefited from TAU and a small number of patients suffered from worsened depressive symptoms at the short term. The results can be included in health-economic models that compare depression treatments to TAU.
引用
收藏
页码:72 / 81
页数:10
相关论文
共 50 条
  • [1] Escitalopram in the treatment of major depressive disorder: A meta-analysis
    Kennedy, Sidney H.
    Andersen, Henning F.
    Thase, Michael E.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 161 - 175
  • [2] Efficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis
    Wang, Shuyu
    Zhang, Wenxing
    Liu, Zhang
    Zhang, Tian
    Wang, Yi
    Li, Weihong
    FRONTIERS IN NEUROSCIENCE, 2024, 17
  • [3] Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis
    Ahmad, Abdullah
    Awan, Abdul Rafeh
    Nadeem, Natasha
    Javed, Aamir Shahid
    Farooqi, Mobeen
    Daniyal, Muhammed
    Mumtaz, Hassan
    FRONTIERS IN NEUROSCIENCE, 2024, 18
  • [4] Theory of mind in major depressive disorder: A meta-analysis
    Bora, Emre
    Berk, Michael
    JOURNAL OF AFFECTIVE DISORDERS, 2016, 191 : 49 - 55
  • [5] Major depressive disorder in epilepsy clinics: A meta-analysis
    Kim, Minjung
    Kim, Young-Soo
    Kim, Do-Hyung
    Yang, Tae-Won
    Kwon, Oh-Young
    EPILEPSY & BEHAVIOR, 2018, 84 : 56 - 69
  • [6] A meta-analysis of emotional reactivity in major depressive disorder
    Bylsma, Lauren M.
    Morris, Bethany H.
    Rottenberg, Jonathan
    CLINICAL PSYCHOLOGY REVIEW, 2008, 28 (04) : 676 - 691
  • [7] Rumination in major depressive and bipolar disorder - a meta-analysis
    Kovacs, Lilla Nora
    Takacs, Zsofia K.
    Toth, Zsofia
    Simon, Evelin
    Schmelowszky, Agoston
    Kokonyei, Gyongyi
    JOURNAL OF AFFECTIVE DISORDERS, 2020, 276 : 1131 - 1141
  • [8] Meta-analysis of genetic studies in major depressive disorder
    Cecile, A.
    Janssens, J. W.
    Leon, Sandra Lopez
    Ladd, Angela M. Gonzalez-Zuloeta
    Del-Favero, Jurgen
    Claes, Stephan
    Oostra, Ben A.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2006, 141B (07) : 693 - 693
  • [9] Treatment Rate for Major Depressive Disorder in China: a Meta-Analysis of Epidemiological Studies
    Han Qi
    Qian-Qian Zong
    Grace K. I. Lok
    Wen-Wang Rao
    Feng-Rong An
    Gabor S. Ungvari
    Lloyd Balbuena
    Qing-E Zhang
    Yu-Tao Xiang
    Psychiatric Quarterly, 2019, 90 : 883 - 895
  • [10] Meta-analysis of the efficacy of escitalopram and citalopram in the treatment of major depressive disorder.
    Kasper, S
    Auquier, P
    Robitail, S
    Llorca, PM
    Rive, B
    NORDIC JOURNAL OF PSYCHIATRY, 2005, 59 (05) : 413 - 413